Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit ...
Fred Hutch researchers show in recent study how aggressive prostate cancer shapeshifts from a form that is treatable with drugs to a more lethal form that is much less treatable. The study also ...
Improving Oncotype DX turnaround time for timeliness of adjuvant therapy: A single-system, multi-site quality improvement study in early-stage HR-positive breast cancer. This is an ASCO Meeting ...
In total, scientists identified eight distinct genetic ‘footprints’ that explain approximately 85 per cent of prostate cancer ...
Prostate cancer screening, test interpretation and treatment decisions can be complex, particularly as new approaches to care ...
Many prostate cancers depend on androgen hormones, including testosterone, to grow. That is why treatments for advanced ...
Lu-177 vipivotide tetraxetan shifted from post-taxane mCRPC to pre-chemotherapy mCRPC and then metastatic hormone-sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results